Study Finds Weight-Loss Drug Semaglutide May Slow Biological Aging in HIV Patients
A recent study has revealed that semaglutide, a GLP-1 drug commonly prescribed for weight loss, may also slow biological aging. Conducted on 108 adults with HIV-associated lipohypertrophy, the study involved administering weekly semaglutide injections over 32 weeks. Researchers used epigenetic clocks, which analyze DNA methylation patterns, to estimate biological aging. The findings indicated that participants receiving semaglutide exhibited slower aging patterns across several epigenetic clocks related to inflammation and major organ systems, including the heart, brain, kidneys, liver, and metabolic system. The pace of biological aging was reduced by approximately 9% according to the DunedinPACE epigenetic clock, with additional reductions noted in age-related disease processes and overall mortality risk.